Role of the high mobility group A proteins in the regulation of pituitary cell cycle

Journal of Molecular Endocrinology

Volumn 44, Issue 6, 2010, Pages 309-318

  Fedele, Monica ^a,b   Fusco, Alfredo ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN B2; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; HIGH MOBILITY GROUP A PROTEIN; HISTONE ACETYLTRANSFERASE; RETINOBLASTOMA PROTEIN; SECURIN; UBIQUITIN PROTEIN LIGASE;

ACETYLATION; ADENOMA; ALLELE; ANAPHASE; BREAST FIBROADENOMA; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL RENEWAL; CHROMATID; DEACETYLATION; DIPLOIDY; DNA SYNTHESIS; EMBRYO DEVELOPMENT; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE SILENCING; GENETIC CODE; HETEROZYGOTE; HUMAN; HYPOPHYSIS CELL; IMMUNOHISTOCHEMISTRY; LIPOMA; LIPOMATOSIS; METAPHASE; METASTASIS; MITOSIS; NONHUMAN; PANCREAS CARCINOMA; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SALIVARY GLAND; STEM CELL; T CELL LYMPHOMA; TETRASOMY; THYROID CELL; TRISOMY 12; UPREGULATION; WESTERN BLOTTING;

ADENOMA; ADULT; ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN D3; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HMGA PROTEINS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PITUITARY GLAND; PITUITARY NEOPLASMS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 77952751782     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-09-0178     Document Type: Review

References (103)

1. Anand A & Chada K 2000 In vivo modulation of Hmgic reduces obesity. Nature Genetics 24 377-380.
2. Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G & Ono SJ 2000 Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. Journal of Biological Chemistry 275 14394-14400. (Pubitemid 30339724)
3. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC & Chada K 1995 Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82 57-65.
4. Baldassarre G, Fedele M, Battista S, Vecchione A, Klein-Szanto AJ, Santoro M, Waldmann S, Azimi N, Croce CM & Fusco A 2001 Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. PNAS 98 7970-7975. (Pubitemid 32642671)
5. Kip1 in human pituitary adenomas. European Journal of Endocrinology 140 250-255.
6. Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM & Fusco A 1999 The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Research 59 4793-4797. (Pubitemid 29472878)
7. Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Giancotti V & Fusco A 1995 Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Molecular and Cellular Biology 15 1545-1553.
8. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M & Fusco A 2002 Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21 2971-2980. (Pubitemid 34522896)
9. Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes and Development 21 1731-1746.
10. Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC & degli Uberti EC 2005 miR-15a and miR-16-1 down-regulation in pituitary adenomas. Journal of Cellular Physiology 204 280-285.
11. Brugarolas J, Bronson RT & Jacks T 1998 p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. Journal of Cell Biology 141 503-514. (Pubitemid 28237097)
12. Chen J, Hersmus N, Van Duppen V, Caesens P, Denef C & Vankelecom H 2005 The adult pituitary contains a cell population displaying stem/progenitor cell and early embryonic characteristics. Endocrinology 146 3985-3998. (Pubitemid 41175770)
13. Chen J, Gremeaux L, Fu Q, Liekens D, Van Laere S & Vankelecom H 2009 Pituitary progenitor cells tracked down by side population dissection. Stem Cells 27 1182-1195.
14. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM & Sherr CJ 1999 The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO Journal 18 1571-1583.
15. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S & Melmed S 2008 p21(Cip1) restrains pituitary tumor growth. PNAS 105 17498-17503.
16. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M et al. 1996 High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13 2439-2446.
17. Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis. Cell Cycle 6 750-757.
18. De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Martinez Hoyos J, Forzati F, Croce CM & Fusco A 2009a Regulation of microRNA expression by HMGA1 proteins. Oncogene 28 1432-1442.
19. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A et al. 2009b HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Research 69 1844-1850.
20. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, Mount M & Melmed S 2006 Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147 4781-4791. (Pubitemid 44402185)
21. Elton TS, Nissen MS & Reeves R 1987 Specific A.T DNA sequence binding of RP-HPLC purified HMG-I. Biochemical and Biophysical Research Communications 143 260-265. (Pubitemid 17030492)
22. Farrell WE & Clayton RN 2003 Epigenetic change in pituitary tumorigenesis. Endocrine-Related Cancer 10 323-330.
23. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E et al. 2002 Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21 3190-3198. (Pubitemid 34548089)
24. Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJ, Kenyon L, Visone R, De Martino I, Ciarmiello A, Arra C et al. 2005 Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24 3427-3435. (Pubitemid 40756244)
25. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM et al. 2006 HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9 459-471. (Pubitemid 43832192)
26. Fedele M, De Martino I, Pivonello R, Ciarmiello A, Del Basso De Caro ML, Visone R, Palmieri D, Pierantoni GM, Arra C, Schmid HA et al. 2007 SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clinical Cancer Research 13 2738-2744. (Pubitemid 46788042)
27. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM et al. 1996 A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85 733-744. (Pubitemid 126334353)
28. Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M, Valtorta E, Mortini P, Croce CM, Larizza L et al. 2002 The high mobility group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Research 62 2398-2405. (Pubitemid 34411724)
29. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L & Xiong Y 1998 CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes and Development 12 2899-2911. (Pubitemid 28440148)
30. Franklin DS, Godfrey VL, O'Brien DA, Deng C & Xiong Y 2000 Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Molecular and Cellular Biology 20 6147-6158. (Pubitemid 30613062)
31. Fusco A & Fedele M 2007 Roles of HMGA proteins in cancer. Nature Reviews. Cancer 7 899-910.
32. Hartwell LH & Weinert TA 1989 Checkpoints: controls that ensure the order of cell cycle events. Science 246 629-634.
33. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN & Farrell WE 1999 Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clinical Cancer Research 5 2133-2139.
34. Holt LJ, Krutchinsky AN & Morgan DO 2008 Positive feedback sharpens the anaphase switch. Nature 454 353-357.
35. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA & Weinberg RA 1992 Effects of an Rb mutation in the mouse. Nature 359 295-300.
36. INK4a. Nature 443 421-426.
37. Johnson KR, Lehn DA & Reeves R 1989 Alternative processing of mRNAs encoding mammalian chromosomal high- mobility-group proteins HMG-I and HMG-Y. Molecular and Cellular Biology 9 2114-2123. (Pubitemid 19117812)
38. Jordan S, Lidhar K, Korbonits M, Lowe DG & Grossman AB 2000 Cyclin D and cyclin E expression in normal and adenomatous pituitary. European Journal of Endocrinology 143 R1-R6.
39. Kaddar T, Rouault JP, Chien WW, Chebel A, Gadoux M, Salles G, Ffrench M & Magaud JP 2009 Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation. Biology of the Cell 101 511-524.
40. Kazmierczak B, Wanschura S, Rommel B, Bartnitzke S & Bullerdiek J 1996 Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its immediate surroundings. Journal of the National Cancer Institute 88 1234-1236. (Pubitemid 26302038)
41. Kazmierczak B, Dal Cin P, Wanschura S, Borrmann L, Fusco A, Van den Berghe H & Bullerdiek J 1998 HMGY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes, Chromosomes and Cancer 23 279-285. (Pubitemid 28507366)
42. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA & Koff A 1996 Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85 721-732. (Pubitemid 126334352)
43. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX & Grossman AB 2002 Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 87 2635-2643. (Pubitemid 34655325)
44. Lazzerini Denchi E, Attwooll C, Pasini D & Helin K 2005 Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Molecular and Cellular Biology 25 2660-2672. (Pubitemid 40381630)
45. Lee YS & Dutta A 2007 The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes and Development 21 1025-1030. (Pubitemid 46686471)
46. Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA & Dynlacht BD 2002 E2F4 loss suppresses tumorigenesis in Rb mutant mice. Cancer Cell 2 463-472.
47. Leung SW, Wloga EH, Castro AF, Nguyen T, Bronson RT & Yamasaki L 2004 A dynamic switch in Rb+/- mediated neuroendocrine tumorigenesis. Oncogene 23 3296-3307. (Pubitemid 38669819)
48. Levy A 2002 Physiological implications of pituitary trophic activity. Journal of Endocrinology 174 147-155. (Pubitemid 34965755)
49. Liau SS, Jazag A, Ito K & Whang EE 2007 Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. British Journal of Cancer 96 993-1000. (Pubitemid 46452287)
50. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM et al. 1999 Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 84 3823-3830. (Pubitemid 30645248)
51. Machiavelli G, Cotignola J, Danilowicz K, Carbonara C, Paes de Lima A, Basso A, Bruno OD & Szijan I 2008 Expression of p16(INK4A) gene in human pituitary tumours. Pituitary 11 71-75.
52. Macias E, de Marval PL, Senderowicz A, Cullen J & Rodriguez-Puebla ML 2008 Expression of CDK4 or CDK2 in mouse oral cavity is retained in adult pituitary with distinct effects on tumorigenesis. Cancer Research 68 162-171. (Pubitemid 351380117)
53. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D & Harel-Bellan A 1998 Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391 601-605. (Pubitemid 28157604)
54. Malumbres M & Barbacid M 2001 To cycle or not to cycle: a critical decision in cancer. Nature Reviews. Cancer 1 222-231. (Pubitemid 33741897)
55. Manfioletti G, Giancotti V, Bandiera A, Buratti E, Sautiere P, Cary P, Crane-Robinson C, Coles B & Goodwin GH 1991 cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Research 19 6793-6797. (Pubitemid 21913116)
56. Martínez-Balbás MA, Bauer UM, Nielsen SJ, Brehm A & Kouzarides T 2000 Regulation of E2F1 activity by acetylation. EMBO Journal 19 662-671.
57. Mayr C, Hemmann MT & Bartel DP 2007 Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315 1576-1579. (Pubitemid 46449474)
58. Morgan DO 1997 Cyclin-dependent kinases: engines, clocks, and microprocessors. Annual Review of Cell and Development Biology 13 261-291.
59. Morris DG, Musat M, Czirják S, Hanzély Z, Lillington DM, Korbonits M & Grossman AB 2005 Differential gene expression in pituitary adenomas by oligonucleotide array analysis. European Journal of Endocrinology 153 143-151. (Pubitemid 41030525)
60. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY & Nakayama K 1996 Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 707-720. (Pubitemid 126334351)
61. Neto AG, McCutcheon IE, Vang R, Spencer ML, Zhang W & Fuller GN 2005 Elevated expression of p21 (WAF1/Cip1) in hormonally active pituitary adenomas. Annals of Diagnostic Pathology 9 6-10. (Pubitemid 40203023)
62. Nishino J, Kim I, Chada K & Morrison SJ 2008 Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf expression. Cell 135 227-239.
63. Norbury C & Nurse P 1992 Animal cell cycles and their control. Annual Review of Biochemistry 61 441-470.
64. Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, Yokoyama T & Fukushima T 2005 The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. Journal of Neuropathology and Experimental Neurology 64 398-403. (Pubitemid 40629130)
65. Pardee AB 1974 A restriction point for control of normal animal cell proliferation. PNAS 71 1286-1290.
66. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C & Koff A 1999 p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. PNAS 96 6382-6387. (Pubitemid 29256674)
67. Pei L & Melmed S 1997 Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 11 433-441. (Pubitemid 27147011)
68. Pierantoni GM, Finelli P, Valtorta E, Giardino D, Rodeschini O, Esposito F, Losa M, Fusco A & Larizza L 2005 High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocrine-Related Cancer 12 867-874. (Pubitemid 41815781)
69. Pines J & Hunter T 1989 Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 58 833-846. (Pubitemid 19227894)
70. Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, Wang EL, Rahman MM, Inoue H, Itakura M et al. 2009 Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Modern Pathology 22 431-441.
71. Quereda V & Malumbres M 2009 Cell cycle control of pituitary development and disease. Journal of Molecular Endocrinology 42 75-86.
72. Ramsey MR, Krishnamurthy J, Pei XH, Torrice C, Lin W, Carrasco DR, Ligon KL, Xiong Y & Sharpless NE 2007 Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Cancer Research 67 4732-4741. (Pubitemid 46910180)
73. Rane SG, Cosenza SC, Mettus RV & Reddy EP 2002 Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Molecular and Cellular Biology 22 644-656.
74. Reeves R & Nissen MS 1990 The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. Journal of Biological Chemistry 265 8573-8582. (Pubitemid 20167366)
75. Rommel B, Rogalla P, Jox A, Kalle CV, Kazmierczak B, Wolf J & Bullerdiek J 1997 HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leukemia & Lymphoma 26 603-607. (Pubitemid 27477785)
76. Saeger W, Schreiber S & Lüdecke DK 2001 Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas. Endocrine Pathology 12 39-47. (Pubitemid 32547894)
77. Sasaki F 1988 Changes with age in the number and size of anterior pituitary cells in female mice from suckling to adulthood. Journal of Endocrinology 117 5-10.
78. Scala S, Portella G, Fedele M, Chiappetta G & Fusco A 2000 Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. PNAS 97 4256-4261. (Pubitemid 30226120)
79. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H & Van de Ven WJ 1995 Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nature Genetics 10 436-444.
80. Sherr CJ & Roberts JM 1999 CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development 13 1501-1512.
81. Simpson DJ, Bicknell JE, McNicol AM, Clayton RN & Farrell WE 1999a Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes, Chromosomes and Cancer 24 328-336.
82. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN & Farrell WE 1999b Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas. Cancer Research 59 1562-1566. (Pubitemid 29160126)
83. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN & Farrell WE 2000 Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Research 60 1211-1216.
84. Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN & Farrell WE 2001 Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 22 1149-1154.
85. Sotillo R, Dubus P, Martín J, de la Cueva E, Ortega S, Malumbres M & Barbacid M 2001 Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO Journal 20 6637-6647. (Pubitemid 33134194)
86. kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Research 65 3846-3852.
87. Thanos D & Maniatis T 1995 Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83 1091-1100. (Pubitemid 26007801)
88. 1/S cell phase transition. Oncogene 26 5596-5605.
89. Turner HE, Nagy Z, Sullivan N, Esiri MM & Wass JA 2000 Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clinical Endocrinology 53 337-344.
90. Uhlmann F, Lottspeich F & Nasmyth K 1999 Sister-chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1. Nature 400 37-42. (Pubitemid 29315102)
91. Vidal A & Koff A 2000 Cell-cycle inhibitors: three families united by a common cause. Gene 247 1-15. (Pubitemid 30201556)
92. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C, Figarella-Branger D et al. 2007 A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-Related Cancer 14 887-900. (Pubitemid 350074076)
93. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269 1281-1284.
94. Woloschak M, Yu A & Post KD 1997 Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Molecular Carcinogenesis 19 221-224. (Pubitemid 27391999)
95. Wood LJ, Maher JF, Bunton TE & Resar LM 2000 The oncogenic properties of the HMG-I gene family. Cancer Research 60 4256-4261.
96. Xu Y, Sumter TF, Bhattacharya R, Tesfaye A, Fuchs EJ, Wood LJ, Huso DL & Resar LM 2004 The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Research 64 3371-3375. (Pubitemid 38657906)
97. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E & Jacks T 1998 Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. Nature Genetics 18 360-364. (Pubitemid 28158165)
98. Yoshino A, Katayama Y, Ogino A, Watanabe T, Yachi K, Ohta T, Komine C, Yokoyama T & Fukushima T 2007 Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. Journal of Neuro-Oncology 83 153-162. (Pubitemid 46784988)
99. Zaidi MR, Okada Y & Chada KK 2006 Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Research 66 7453-7459. (Pubitemid 44289198)
100. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD & Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 761-767. (Pubitemid 29075718)
101. Zhou X, Benson KF, Ashar HR & Chada K 1995 Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376 771-774.
102. Zhu X, Mao X, Hurren R, Schimmer AD, Ezzat S & Asa SL 2008 Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. Journal of Clinical Endocrinology and Metabolism 93 3610-3617.
103. Zou H, McGarry TJ, Bernal T & Kirschner MW 1999 Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285 418-422.